Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07600190 · ClinicalTrials.gov registry record · Phase 1
Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Not yet
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT07600190 is a Phase 1 study that has not yet begun recruiting, run by University of North Carolina, Chapel Hill. The registered enrollment target is 60 participants.
The verdict
NCT07600190, a Phase 1 study, has not yet begun recruiting, sponsored by University of North Carolina, Chapel Hill.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
In this single center, interventional pilot study, 40 participants at high risk for future exacerbation will be randomized to anakinra (v. placebo control) treatment for home administration as part of an asthma action plan (AAP) and monitored through their first moderate asthma exacerbation, triggering treatment dosing over a 26 week period. Key feasibility questions will be assessed in this pilot study to inform trial design and sample size selection for a future multi-site phase II clinical trial testing anakinra as a rescue treatment for moderate asthma exacerbations.
Interventions
- DRUG Anakinra 100 Mg/0.67 Ml Inj Syringe
- DRUG Saline Placebo/0.67 Ml Inj Syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07600190
The ClinicalTrials.gov registry entry for NCT07600190 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Anakinra 100 Mg/0.67 Ml Inj Syringe is the first listed.
NCT07600190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07600190 about?
NCT07600190 is a clinical study titled "Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)". In this single center, interventional pilot study, 40 participants at high risk for future exacerbation will be randomized to anakinra (v. placebo control) treatment for home administration as part of an asthma action plan (AAP) and monitored through their first moderate asthma exacerbation, trigger...
What is the current status of trial NCT07600190?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2026-06-01. Estimated completion is 2028-12-01.
What interventions are being tested in trial NCT07600190?
The interventions under investigation include: Anakinra 100 Mg/0.67 Ml Inj Syringe (DRUG), Saline Placebo/0.67 Ml Inj Syringe (DRUG).
Who is sponsoring clinical trial NCT07600190?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.